Trade

with

Cesca Therapeutics Inc
(Germany: THRA)
AdChoices
=
0.9000
0.0000
0.00%
After Hours :
-
-
-

Open

0.9000

Previous Close

0.9000

Volume (Avg)

0 (-)

Day's Range

0.9000-0.9000

52Wk Range

-

Market Cap.

36.24M

Dividend Rate ( Yield )

-

Beta

-0.42

Shares Outstanding

40.27M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Devices
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 12.63M

    • Net Income

    • -6.82M

    • Market Cap.

    • 36.24M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -53.99

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.42

    • Forward P/E

    • -3.81

    • Price/Sales

    • 1.73

    • Price/Book Value

    • 0.95

    • Price/Cash flow

    • -3.54

      • EBITDA

      • -6.36M

      • Return on Capital %

      • -21.20

      • Return on Equity %

      • -27.83

      • Return on Assets %

      • -21.20

      • Book Value/Share

      • 0.75

      • Shares Outstanding

      • 40.27M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 4.74

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.23

        • Cashflow Estimate

        • -0.15

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

          • Sales (Revenue)

            Q/Q (last year)

          • -7.50

          • Net Income

            YTD/YTD (last year)

          • -

          • Net Income

            Q/Q (last year)

          • -

          • Sales (Revenue)

            5-Year Annual Average

          • -4.19

          • Net Income

            5-Year Annual Average

          • -

          • Dividends

            5-Year Annual Average

          • -

          • Profit Margins (%)

          • Company

            • Gross Margin

            • 36.82

            • Pre-Tax Margin

            • -56.51

            • Net Profit Margin

            • -53.99

            • Average Gross Margin

              5-Year Annual Average

            • 35.10

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • Average Net Profit Margin

              5-Year Annual Average

            • -26.20

            • Financial Ratios

            • Company

              • Debt/Equity Ratio

              • -

              • Current Ratio

              • 3.97

              • Quick Ratio

              • 3.06

              • Interest Coverage

              • -

              • Leverage Ratio

              • 1.29

              • Book Value/Share

              • 0.95

              • Price Ratios

              • Company

                • Current P/E Ratio

                • -3.21

                • P/E Ratio 5-Year High

                • -10.09

                • P/E Ratio 5-Year Low

                • -1.20

                • Price/Sales Ratio

                • 1.73

                • Price/Book Value

                • 0.95

                • Price/Cash Flow Ratio

                • -3.54

                • Key Metrics

                • Company

                  • Return on Equity %

                    (5-Year Average)

                  • -27.83

                    (-23.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -21.20

                    (-17.90)

                  • Return on Capital %

                    (5-Year Average)

                  • -27.83

                    (-23.20)

                  • Income/Employee

                  • -

                  • Inventory Turnover

                  • 2.05

                  • Asset Turnover

                  • 0.39

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -7.14M
                  Operating Margin
                  -56.55
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -3.54
                  Ownership

                  Institutional Ownership

                  13.01%

                  Top 10 Institutions

                  12.87%

                  Mutual Fund Ownership

                  1.67%

                  Float

                  71.15%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    438,429

                  • 0.00

                  • 1.09

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    63,283

                  • 0.00

                  • 0.16

                  • Vanguard Extended Market Index Fund

                  •  

                    54,283

                  • 0.00

                  • 0.13

                  • AQR Small Cap Momentum Fund

                  •  

                    18,100

                  • 0.00

                  • 0.05

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    15,844

                  • 0.00

                  • 0.04

                  • Vanguard Instl Total Stock Market Index

                  •  

                    14,114

                  • 0.00

                  • 0.04

                  • EB DL Non-SL Market Completion Fund

                  •  

                    12,823

                  • 673.87

                  • 0.03

                  • Wilshire Micro-Cap ETF

                  •  

                    7,068

                  • 0.00

                  • 0.02

                  • AXA/Lord Abbett Micro Cap Portfolio

                  •  

                    4,650

                  • 22.95

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sabby Management LLC

                  •  

                    3,317,805

                  • +526.83%

                  • 8.25

                  • BlackRock Fund Advisors

                  •  

                    1,043,735

                  • +13.73%

                  • 2.60

                  • Vanguard Group, Inc.

                  •  

                    457,554

                  • +48.17%

                  • 1.14

                  • Geode Capital Management, LLC

                  •  

                    80,228

                  • 0.00%

                  • 0.20

                  • California Public Employees Retrmnt Sys

                  •  

                    49,674

                  • 0.00%

                  • 0.12

                  • Northern Trust Investments, N.A.

                  •  

                    28,672

                  • 0.00%

                  • 0.07

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Devices

                  Type

                  Distressed

                  Style

                  Small Value

                  Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It ...moreserves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets....more The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.lessless

                  Key People

                  Matthew T. Plavan

                  CEO/Director

                  Craig W. Moore

                  Chairman of the Board/Director

                  Dan T. Bessey

                  CFO/Chief Accounting Officer

                  Kevin Cooksy

                  Vice President, Divisional

                  Kenneth Pappa

                  Vice President, Divisional

                  • Cesca Therapeutics Inc

                  • 2711 Citrus Road

                  • Rancho Cordova, CA 95742

                  • USA.Map

                  • Phone: +1 916 858-5100

                  • Fax: +1 916 858-5199

                  • cescatherapeutics.com

                  Incorporated

                  1986

                  Employees

                  95

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: